AFF3 upregulation mediates tamoxifen resistance in breast cancers

Abstract excerpt

Although tamoxifen is a highly effective drug for treating estrogen receptor–positive (ER + ) breast cancer, nearly all patients with metastasis with initially responsive tumors eventually relapse, and die from acquired drug resistance. Unfortunately, few molecular mediators of tamoxifen resistance have been described. Here, we describe AFF3 (AF4/FMR2 family member 3), which encodes a nuclear protein with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HER2/EGFR in Cancer Research
• Share to Signaling Pathways in Disease
• Share to Wnt/β-catenin signaling in development and cancer